Harmful alcohol breakdown chemicals and gut immune changes in liver damage
Aldehydes in Alcohol-Induced Organ Injury
Looks at whether aldehydes (alcohol breakdown chemicals) and changes in gut immune cells help drive liver damage in people who drink heavily.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Greensboro NIH-funded |
| Lab location | 1 site (Greensboro, United States) |
| Project ID | NIH-11326630 on NIH RePORTER |
What this research studies
From my perspective, the team studies how alcohol-caused chemicals called aldehydes and changes in gut immune cells harm the gut–liver connection and lead to alcoholic liver disease. They use mouse models with specific immune cell changes, transfer immune cells back into animals, give treatments like IFN-gamma, and examine effects on gut bacteria, gut barrier function, and liver inflammation. The work also links those preclinical findings to human alcoholic liver disease to guide future approaches. The goal is to find targets that could be translated into new treatments for people with alcohol-related liver injury.
Who could benefit from this research
Good fit: Adults with a history of heavy alcohol use or a diagnosis of alcoholic liver disease (from fatty liver to alcoholic hepatitis or cirrhosis) would be the main group who could benefit or be recruited for related clinical work.
Not a fit: People whose liver disease is due to nonalcohol causes (for example viral hepatitis or nonalcoholic fatty liver disease) or casual/light drinkers are unlikely to benefit from these alcohol-specific findings.
Why it matters
Potential benefit: If successful, this work could point to new ways to protect the gut–liver axis and lead to treatments that reduce inflammation and slow or prevent progression of alcoholic liver disease.
How similar studies have performed: Prior animal studies have shown that restoring certain gut dendritic cells or giving IFN-gamma can improve gut barrier function and reduce liver inflammation, but clinical testing in people is still limited.
Where this research is happening
Greensboro, United States
- University of North Carolina Greensboro — Greensboro, United States (Active)
Researchers
- Principal investigator: Zhou, Zhanxiang — University of North Carolina Greensboro
- Study coordinator: Zhou, Zhanxiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.